In this articleRXRXFollow your favorite stocksCREATE FREE ACCOUNTSource: Recursion PharmaceuticalsAI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone.Recursion was able to use its artificial intelligence-enabled drug discovery platform to identify an area of biology to target for the treatment of solid tumors and lymphoma, match it with a drug candidate and move all the way to gaining regulatory approval to begin studies in less than 18 months.'We think that's a really exciting proof point, not only for us as a company, but I think for the techbio industry as well,' said CEO and co-founder Chris Gibson, in an interview with CNBC.The Food and Drug Administration cleared the investigational new drug application for a phase 1/2 clinical trial of an experimental drug candidate known as REC-1245.

在这篇文章中，RXRX跟随你最喜欢的股票创建免费账户来源：Recursion PharmaceuticalsAI药物先驱Recursion Pharmaceuticals周三表示，其一种实验性治疗方法达到了一个关键的里程碑。Recursion能够使用其人工智能药物发现平台来确定实体瘤和淋巴瘤治疗的生物学领域，将其与候选药物进行匹配，并一直获得监管部门的批准，在不到18个月的时间内开始研究。”。美国食品和药物管理局（FDA）批准了一项实验候选药物REC-1245的1/2期临床试验的研究性新药申请。

The company said the potential market for this treatment could be more than 100,000 patients in the U.S. and European Union.The trial will evaluate the safety and tolerability of REC-1245 and will begin in the fourth quarter of this year. The phase 1 data from the dose-escalation portion of the study could be completed by the end of next year, the company has said.The drug will target RBM39, which Recursion said appears functionally similar to a well-known but hard to target marker known as CDK12 to treat advanced HR-proficient cancers such as ovarian, prostate, breast and pancreatic cancers.'I think what's really exciting about this particular program of Recursion is that this small molecule and novel target came out from essentially a Google-search equivalent, from this giant map of biology that we've already built,' Gibson said, referring to the massive datasets that Recursion has created over the past 11 years.'Thi.

该公司表示，这种治疗方法在美国和欧盟的潜在市场可能超过10万名患者。该试验将评估REC-1245的安全性和耐受性，并将于今年第四季度开始。该公司表示，该研究剂量递增部分的第一阶段数据可能在明年年底完成。该药物将靶向RBM39，Recursion说RBM39在功能上类似于众所周知但难以靶向的CDK12标记物，用于治疗晚期HR熟练的癌症，如卵巢癌、前列腺癌、乳腺癌和胰腺癌吉布森（Gibson）说，我认为这个特定的递归程序真正令人兴奋的是，这个小分子和新颖的目标基本上来自谷歌搜索引擎，来自我们已经构建的这张巨大的生物学地图。吉布森指的是递归在过去11年中创建的大量数据集这。